|
Gene: INAVA |
Gene summary for INAVA |
Gene summary. |
Gene information | Species | Human | Gene symbol | INAVA | Gene ID | 55765 |
Gene name | innate immunity activator | |
Gene Alias | C1orf106 | |
Cytomap | 1q32.1 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q3KP66 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55765 | INAVA | CCI_1 | Human | Cervix | CC | 8.10e-05 | 6.70e-01 | 0.528 |
55765 | INAVA | CCI_3 | Human | Cervix | CC | 4.32e-09 | 6.41e-01 | 0.516 |
55765 | INAVA | sample3 | Human | Cervix | CC | 1.71e-19 | 3.59e-01 | 0.1387 |
55765 | INAVA | T3 | Human | Cervix | CC | 1.72e-12 | 3.36e-01 | 0.1389 |
55765 | INAVA | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.41e-02 | 1.89e-01 | 0.0155 |
55765 | INAVA | HTA11_2487_2000001011 | Human | Colorectum | SER | 8.32e-24 | 1.03e+00 | -0.1808 |
55765 | INAVA | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.25e-17 | 7.42e-01 | -0.0811 |
55765 | INAVA | HTA11_78_2000001011 | Human | Colorectum | AD | 1.24e-08 | 5.68e-01 | -0.1088 |
55765 | INAVA | HTA11_347_2000001011 | Human | Colorectum | AD | 9.32e-36 | 9.01e-01 | -0.1954 |
55765 | INAVA | HTA11_411_2000001011 | Human | Colorectum | SER | 1.87e-10 | 1.54e+00 | -0.2602 |
55765 | INAVA | HTA11_2112_2000001011 | Human | Colorectum | SER | 3.25e-13 | 1.23e+00 | -0.2196 |
55765 | INAVA | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.39e-12 | 7.05e-01 | -0.1207 |
55765 | INAVA | HTA11_83_2000001011 | Human | Colorectum | SER | 1.10e-09 | 6.37e-01 | -0.1526 |
55765 | INAVA | HTA11_696_2000001011 | Human | Colorectum | AD | 3.38e-23 | 8.29e-01 | -0.1464 |
55765 | INAVA | HTA11_866_2000001011 | Human | Colorectum | AD | 5.77e-16 | 6.29e-01 | -0.1001 |
55765 | INAVA | HTA11_1391_2000001011 | Human | Colorectum | AD | 2.48e-13 | 6.87e-01 | -0.059 |
55765 | INAVA | HTA11_2992_2000001011 | Human | Colorectum | SER | 2.58e-10 | 8.38e-01 | -0.1706 |
55765 | INAVA | HTA11_5212_2000001011 | Human | Colorectum | AD | 4.70e-17 | 1.03e+00 | -0.2061 |
55765 | INAVA | HTA11_546_2000001011 | Human | Colorectum | AD | 1.20e-05 | 5.75e-01 | -0.0842 |
55765 | INAVA | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.55e-03 | 3.10e-01 | 0.0674 |
Page: 1 2 3 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:190332010 | Cervix | CC | regulation of protein modification by small protein conjugation or removal | 66/2311 | 242/18723 | 2.31e-10 | 3.46e-08 | 66 |
GO:003139610 | Cervix | CC | regulation of protein ubiquitination | 59/2311 | 210/18723 | 5.90e-10 | 7.51e-08 | 59 |
GO:00452169 | Cervix | CC | cell-cell junction organization | 53/2311 | 200/18723 | 3.83e-08 | 2.53e-06 | 53 |
GO:00027644 | Cervix | CC | immune response-regulating signaling pathway | 97/2311 | 468/18723 | 1.49e-07 | 7.07e-06 | 97 |
GO:00018197 | Cervix | CC | positive regulation of cytokine production | 95/2311 | 467/18723 | 4.88e-07 | 1.85e-05 | 95 |
GO:00022379 | Cervix | CC | response to molecule of bacterial origin | 78/2311 | 363/18723 | 5.55e-07 | 2.06e-05 | 78 |
GO:00310988 | Cervix | CC | stress-activated protein kinase signaling cascade | 58/2311 | 247/18723 | 8.02e-07 | 2.89e-05 | 58 |
GO:00305229 | Cervix | CC | intracellular receptor signaling pathway | 60/2311 | 265/18723 | 1.89e-06 | 5.97e-05 | 60 |
GO:00514038 | Cervix | CC | stress-activated MAPK cascade | 55/2311 | 239/18723 | 2.96e-06 | 8.31e-05 | 55 |
GO:00703027 | Cervix | CC | regulation of stress-activated protein kinase signaling cascade | 46/2311 | 195/18723 | 9.35e-06 | 2.11e-04 | 46 |
GO:00018949 | Cervix | CC | tissue homeostasis | 57/2311 | 268/18723 | 2.43e-05 | 4.21e-04 | 57 |
GO:00434104 | Cervix | CC | positive regulation of MAPK cascade | 90/2311 | 480/18723 | 2.92e-05 | 4.83e-04 | 90 |
GO:00328727 | Cervix | CC | regulation of stress-activated MAPK cascade | 44/2311 | 192/18723 | 3.09e-05 | 5.10e-04 | 44 |
GO:00431228 | Cervix | CC | regulation of I-kappaB kinase/NF-kappaB signaling | 53/2311 | 249/18723 | 4.50e-05 | 6.87e-04 | 53 |
GO:00602498 | Cervix | CC | anatomical structure homeostasis | 63/2311 | 314/18723 | 6.03e-05 | 8.68e-04 | 63 |
GO:00022212 | Cervix | CC | pattern recognition receptor signaling pathway | 39/2311 | 172/18723 | 1.08e-04 | 1.38e-03 | 39 |
GO:00072497 | Cervix | CC | I-kappaB kinase/NF-kappaB signaling | 56/2311 | 281/18723 | 1.81e-04 | 2.12e-03 | 56 |
GO:00027534 | Cervix | CC | cytoplasmic pattern recognition receptor signaling pathway | 18/2311 | 60/18723 | 2.26e-04 | 2.55e-03 | 18 |
GO:00725939 | Cervix | CC | reactive oxygen species metabolic process | 47/2311 | 239/18723 | 7.74e-04 | 6.87e-03 | 47 |
GO:00026973 | Cervix | CC | regulation of immune effector process | 62/2311 | 339/18723 | 9.25e-04 | 7.84e-03 | 62 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |